| Literature DB >> 26250696 |
Haki Jashari1, Annika Rydberg2, Pranvera Ibrahimi1, Gani Bajraktari1, Lindita Kryeziu3, Fisnik Jashari1, Michael Y Henein4.
Abstract
AIMS: The definition of normal values of two-dimensional speckle-tracking echocardiography derived left ventricular (LV) deformation parameters, is of critical importance for the routine application of this modality in children. The objectives of this study were to perform a meta-analysis of normal ranges for longitudinal, circumferential and radial strain/strain rate values and to identify confounders that may contribute to differences in reported measures. METHODS ANDEntities:
Mesh:
Year: 2015 PMID: 26250696 PMCID: PMC4528396 DOI: 10.1186/s12947-015-0029-0
Source DB: PubMed Journal: Cardiovasc Ultrasound ISSN: 1476-7120 Impact factor: 2.062
Echocardiographic characteristics
| Study | Year | LV measurements | LV model for LS generation | Segmental LS | Echocardiographic View L/C, R | Vendor | Probe (Mhz) | Software | FR | Tissue tracking |
|---|---|---|---|---|---|---|---|---|---|---|
| Bussadori [ | 2009 | L, C (S, SR) | 6 segments | Yes | Apical 4CH/BMA sax | MyLab 50 | 2.5–3.5 | Xstrain | 40-64 | Endocardial |
| Pettersen [ | 2009 | L, C (S, SR) | Bull’s eye | No | Apical 2,3,4 CH/BMA (G) sax | GE Vivid 7 | NS | EchoPac | 69-112 | Endomyocardial |
| Jin Yu [ | 2010 | C, R (S, SR) | N/A | N/A | /Basal and Mid-level sax | GE Vivid 7 | 5 and 7 | EchoPac | 40-100 | NS |
| Singh [ | 2010 | L, C, (S) | Bull’s eye | Yes | Apical 2,3,4CH/BMA sax | GE Vivid 7 | 4 | EchoPac | 60-90 | Endomyocardial |
| Van der Hulst [ | 2010 | L (S) | Bull’s eye | Yes | Apical 2,3,4 CH | GE Vivid 7 | 3.5 | EchoPac | >40 | Endomyocardial |
| Koh [ | 2010 | L, C (S, SR) | 6 segments | No | Apical 4CH/BMA sax | GE Vivid 7 | NS | EchoPac | NS | NS |
| Cheung [ | 2010 | L, C, R (S, SR) | 6 segments | No | Apical 4CH/Mid-level sax | GE Vivid 7 | NS | EchoPac | NS | NS |
| Marcus [ | 2011 | L, C, R (S) | 6 segments | Yes | Apical 4CH/Basal and Mid-level sax | GE Vivid 7 | 3 or 5 | EchoPac | 70-90 | Endomyocardial |
| Takayasu [ | 2011 | L (S, SR) | 6 segments | No | Apical 4 CH | GE Vivid 7 | UTD | EchoPac | NS | Endomyocardial |
| Di salvo [ | 2012 | L, C, R (S) | 6 segments | Yes | Apical 4CH/BMA sax | GE Vivid 7 | 1.5-4 | EchoPac | 75 (16) | Endomyocardial |
| Fernandes [ | 2012 | C, R (S, SR) | N/A | N/A | /BMA sax | GE Vivid 7 | NS | EchoPac | 60-90 | Endomyocardial |
| Poterucha [ | 2012 | L (S) | Bull’s eye | Yes | Apical 2,3,4 CH | GE Vivid 7 | NS | EchoPac | >80 | NS |
| Hirth [ | 2012 | L (S, SR) | 6 segments | Yes | Apical 4CH | GE Vivid 7 | UTD | EchoPac | 50 | NS |
| Schubert [ | 2013 | L (S, SR) | 6 segments | Yes | Apical 4CH | GE Vivid 7 | 4–10.5 | EchoPac | 176-200 | Endomyocardial |
| Sehgal [ | 2013 | L (S, SR) | 6 segments | Yes | Apical 4CH | GE Vivid 7 | 10 | EchoPac | >80 | NS |
| Klitsie [ | 2013 | L, C, R (S) | 6 segments | No | Apical 4CH/Mid-level sax | GE Vivid 7 | NS | EchoPac | NS | Endomyocardial |
| Klitsie [ | 2013 | L, C, R (S) | 6 segments | No | Apical 4CH/Mid-level sax | GE Vivid 7 | NS | EchoPac | 60-80 | Endomyocardial |
| Singh [ | 2013 | L (S) | Bull’s eye | No | Apical 2,3,4CH | GE Vivid 7 | 1.5-4 | EchoPac | NS | NS |
| Van der Ende [ | 2013 | L (S) | Bull’s eye | Yes | Apical 2,3,4CH | GE Vivid 7 | NS | EchoPac | >45 | NS |
| Dogan [ | 2013 | L, C, R (S, SR) | 6 segments | Yes | Apical 4 CH/Mid-level sax | GE Vivid 7 | 3.0 and 7.5 | EchoPac | >60 | Endomyocardial |
| Barbosa [ | 2013 | L (S) | Bull’s eye | No | Apical 2,3,4 CH | GE Vivid 7 | NS | EchoPac | 44 | NS |
| Ryan [ | 2013 | C (S) | N/A | N/A | /Mid-level sax | Mix | NS | Tomtec | 75 | Endomyocardial |
| McCandless [ | 2013 | L, C (S, SR) | 6 segments | Yes | Apical 4CH/Mid-level sax | Siemens | NS | Syngo | NS | Endocardial |
| Simsek [ | 2013 | L (S, SR) | Bull’s eye | No | Apical 2,3,4 CH | GE Vivid 7 | 2.5 | EchoPac | 60-100 | NS |
| Vitarelli [ | 2014 | L, C, R (S) | Bull’s eye | No | Apical 2,3,4 CH/BMA (G) sax | GE Vivid E9 | 1.4-4.6 | EchoPac | >50 | NS |
| Forsey [ | 2014 | L, C (S) | 6 segments | Yes | Apical 4CH/BMA sax | GE Vivid 7 | NS | EchoPac | 33-129 | Endomyocardial |
| Labombarda [ | 2014 | L, C, R (S) | 6 segments | No | Apical 2,3,4CH/Mid-level sax | Philips iE33 | 1-5 | QLab | NS | Endo-Epicardial |
| Binnetoglu [ | 2015 | L, C, R (S) | 6 segments | Yes | Apical 4 CH/Mid-level sax | GE Vivid 7 | NS | EchoPac | 60-90 | NS |
L Longitudinal, C Circumferential, R Radial, S Strain, SR Strain rate, CH Chamber view, FR Frame rate, BMA Basal, medium and apical level, BMA (G) only global strain value available, Mix three different vendors used (GE, Philips and Acuson), sax short axis, NS not specified, UTD unable to determine
Studies’ Characteristics
| Article | Age group Study | Year | No | Age | Age group | Males % | HR | BSA/Weight | SBP | DBP | LV mass | EDV | ESV | EDD | ESD | Control studied | Disease studied |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| g/m2 | ml/m2 | ml/m2 | |||||||||||||||
| 1 | Bussadori [ | 2009 | 15 | 8 ± 2 y | 5-9 y | 53 | Healthy Subjects | Healthy Pediatric Cohort | |||||||||
| 2 | Pettersen [ | 2009 | 22 | 12.7 ± 2.3 y | 10-14 y | 63 | 1.44 ± 0.24 | 108 ± 12 | 63 ± 7 | 58 ± 8 | 26 ± 4 | Healthy Controls | Transposition of the Great Arteries | ||||
| 3 | Jin Yu [ | 2010 | 35 | 2.6 ± 1.6 y | 1-4 y | 48 | 0.59 ± 0.15 | 59.5 ± 12.2 | 31.1 ± 5 | 19.7 ± 3.3 | Healthy Controls | Kawasaki Disease | |||||
| 4 | Van der Hulst [ | 2010 | 19 | 14.1 ± 2.4 y | 10-14 y | 63 | 1.6 ± 0.3 | 95 ± 10 | 42 ± 7 | Healthy Controls | Tetralogy of Fallot | ||||||
| 5 | Koh [ | 2010 | 9 | 5.5 ± 5.5 y | 5-9 y | 22 | 0.81 ± 0.44 | Healthy Controls | Left ventricular non-compaction | ||||||||
| 6 | Singh [ | 2010 | 14 | 15 y | 15-19 y | 45 | 75 | 1.22 (1.1-1.6) | Healthy Controls | Single ventricle s/p Fontan procedure. | |||||||
| 7 | Cheung [ | 2010 | 44 | 16.4 ± 6.9 y | 15-19 y | 48 | 54.1 ± 11.9 | 45 ± 5 | 28 ± 4 | Healthy Controls | Anthracycline Therapy | ||||||
| 8 | Takayasu [ | 2011 | 12 | 7.4 ± 1.7 y | 5-9 y | 66 | 46.7 ± 4.8 | 13.5 ± 1.5 | Healthy Controls | Repaired Tetralogy of Fallot | |||||||
| 8 | Takayasu [ | 2011 | 19 | 15.5 ± 4.1 y | 15-19 y | 70 | 54.9 ± 7.7 | 15 ± 2.6 | Healthy Controls | Repaired Tetralogy of Fallot | |||||||
| 9 | Marcus [ | 2011 | 24 | 0.3 ± 0.3 y | 0-1 y | 54 | 118 | 0.32 ± 0.1 | 82.8 ± 8 | 56 ± 6 | 36.2 ± 12.1 | Healthy Subjects | Healthy Pediatric Cohort | ||||
| 9 | Marcus [ | 2011 | 34 | 2.9 ± 1.0 y | 1-4 y | 56 | 101 | 0.62 ± 0.1 | 98 ± 10 | 62 ± 10 | 48.5 ± 11.6 | Healthy Subjects | Healthy Pediatric Cohort | ||||
| 9 | Marcus [ | 2011 | 36 | 7.2 ± 1.2 y | 5-9 y | 69 | 84 | 0.93 ± 0.12 | 104 ± 8 | 70 ± 8 | 57.2 ± 12.3 | Healthy Subjects | Healthy Pediatric Cohort | ||||
| 9 | Marcus [ | 2011 | 29 | 12.8 ± 1.6 y | 10-14 y | 55 | 77 | 1.43 ± 0.23 | 110 ± 10 | 72 ± 8 | 59.9 ± 14.2 | Healthy Subjects | Healthy Pediatric Cohort | ||||
| 9 | Marcus [ | 2011 | 21 | 17 ± 1.3 y | 15-19 y | 43 | 65 | 1.81 ± 0.2 | 116 ± 10 | 75 ± 9 | 71.8 ± 16 | Healthy Subjects | Healthy Pediatric Cohort | ||||
| 10 | Di Salvo [ | 2012 | 45 | 11 ± 3 y | 10-14 y | 65 | 78 | 1.32 ± 0.4 | 107 ± 14 | 61 ± 8 | 72 ± 15 | 38.9 ± 6.2 | Healthy Controls | Heterozygous Familial Hypercholesterolemia | |||
| 11 | Fernandes [ | 2012 | 71 | 10 ± 5 y | 10-14 y | Healthy Controls | Tetralogy of Fallot | ||||||||||
| 12 | Poterucha [ | 2012 | 19 | 15.3 ± 3 y | 15-19 y | 57 | 62 | 1.7 ± 0.3 | 119 ± 12 | 48 ± 5 | 30 ± 3.4 | Healthy Controls | Anthracycline Chemotherapy | ||||
| 13 | Hirth [ | 2012 | 34 | 11.7 ± 3.8 y | 10-14 y | 62 | 70 | 1.41 ± 0.39 | 72.3 ± 16.9 | Healthy Controls | Renal Transplantation in Childhood | ||||||
| 14 | Schubert [ | 2013 | 30 | 135-207 h | Neonates | 36 | Healthy Neonates | Fetuses | |||||||||
| 15 | Sehgal [ | 2013 | 21 | 2-5 d | Neonates | 3912 g | Healthy Controls | Asphyxiated Infants | |||||||||
| 16 | Klitsie [ | 2013 | 28 | 1-3 d | Neonates | 36 | 123 | 3500 g | Healthy Subjects | Healthy Newborns | |||||||
| 17 | Klitsie [ | 2013 | 37 | 0.1-0.3 y | 0-1 y | 46 | 148 | 0.3 ± 0.1 | Healthy Subjects | Healthy Pediatric Cohort | |||||||
| 17 | Klitsie [ | 2013 | 35 | 2.3-3.8 y | 1-4 y | 54 | 107 | 0.6 ± 0.1 | Healthy Subjects | Healthy Pediatric Cohort | |||||||
| 17 | Klitsie [ | 2013 | 37 | 6.2-8.2 y | 5-9 y | 54 | 88 | 0.9 ± 0.2 | Healthy Subjects | Healthy Pediatric Cohort | |||||||
| 17 | Klitsie [ | 2013 | 45 | 11.1-13.8 y | 10-14 y | 76 | 71 | 1.4 ± 02 | Healthy Subjects | Healthy Pediatric Cohort | |||||||
| 17 | Klitsie [ | 2013 | 18 | 15.9-16.9 y | 15-19 y | 44 | 71 | 1.8 ± 0.2 | Healthy Subjects | Healthy Pediatric Cohort | |||||||
| 18 | Singh [ | 2013 | 20 | 12.9 y | 10-14 y | 45 | 75 | 1.22 | 109 ± 11 | 68 ± 5 | Healthy Subjects | Tricuspid Atresia s/p Fontan procedure | |||||
| 19 | Van der Ende [ | 2013 | 40 | 8.4 ± 4 y | 5-9 y | 53 | 1.07 ± 0.34 | Healthy Controls | Aortic Stenosis and Coarctation of Aorta | ||||||||
| 20 | Dogan [ | 2013 | 52 | 6.4 ± 3.8 y | 5-9 y | 75 | 101 | 0.87 ± 0.32 | 56.1 ± 18.4 | 33.8 ± 7.4 | 17.8 ± 5.8 | Healthy Controls | Aortic Stenosis | ||||
| 21 | Barbosa [ | 2013 | 46 | 11.5 ± 3.1 y | 10-14 y | 74 | 90.5 ± 10 | 58.1 ± 6.3 | 40.7 ± 5.6 | 25.9 ± 3.3 | Healthy Controls | Obese Patients | |||||
| 22 | McCandless [ | 2013 | 22 | 12-29 m | 1-4 y | 55 | 0.48 | Healthy Controls | Kawasaki Disease | ||||||||
| 23 | Ryan [ | 2013 | 61 | 5.2 ± 0.2 y | 5-9 y | 100 | 87 | 104 ± 1 | 60.9 ± 0.9 | Healthy Controls | Duchenne Muscular Dystrophy | ||||||
| 24 | Simsek [ | 2013 | 20 | 16.4 ± 1.8 y | 15-19 y | 100 | 65 | 115 ± 10 | 70.5 ± 6 | 88 ± 14 | 46.7 ± 4.7 | 29.3 ± 4.3 | Healthy Controls | Young Elite Athletes | |||
| 25 | Vitarelli [ | 2014 | 40 | 11.3 ± 2.8 y | 10-14 y | 55 | 76 | 103 ± 1.6 | 67.3 ± 1.4 | 54.1 ± 14.1 | 57.2 ± 9.5 | 41.2 ± 5.3 | Healthy Controls | Hypercholesterolemic and Obese Children | |||
| 26 | Forsey [ | 2014 | 28 | 9.8 ± 4.4 y | 5-9 y | 82 | 1.16 ± 0.4 | 64.3 ± 11.5 | 41.8 ± 5.7 | Healthy Controls | Hypertrophic Cardiomyopathy Mutations | ||||||
| 27 | Labombarda [ | 2014 | 79 | 11.8 ± 3.2 y | 10-14 y | 53 | 76 | 1.27 ± 0.29 | 109 ± 11 | 62.9 ± 8.1 | 42.5 ± 6.7 | Healthy Controls | Diabetic Children | ||||
| 28 | Binnetoglu [ | 2015 | 31 | 15 (11-16) y | 15-19 y | 67 | 1.48 ± 0.24 | 110 (80-129) | 60 (48-80) | 67.7 ± 13 | 42.2 ± 2.48 | 26.1 ± 3.74 | Healthy Controls | Obese Children and Adolescents |
HR heart rate, BSA Body surface area, SBP systolic blood pressure, DBP diastolic blood pressure, EDV end diastolic volume, ESV end systolic volume, EDD end diastolic diameter, ESD end systolic diameter
Fig. 1Paper selection flowchart
Fig. 2Normal value of LS. The forest plot lists the names of the studies in subgroups. The means and CIs including the results for variance, used in the inverse variance correction are shown
Meta-regression results (p values). Significant p-values are bolded for emphasis
| LS | LSRs | CS | RS | |||||
|---|---|---|---|---|---|---|---|---|
| Variable | b (95 % CI) | p | b (95 % CI) | p | b (95 % CI) | p | b (95 % CI) | p |
| Age | 0.06 (-0.03 to 0.16) | 0.18 | 0.04 (0.02 to 0.05) |
| -0.07 (-0.26 to -0.11) | 0.45 | 0.16 (-1.01 to 1.33) | 0 |
| Male gender | 0.02 (-0.02 to 0.06) | 0.31 | 0.002 (-0.004 to 0.009) | 0.49 | -0.01 (-0.07 to 0.05) | 0.76 | 0.13 (-0.7 to 0.95) | 0.75 |
| BSA | -0.24 (-1.64 to 1.15) | 0.73 | -1.71 (-4.25 to 0.82) | 0.18 | 0.14 (-15.59 to 15.87) | 0.98 | ||
| HR | -0.004 (-0.03 to 0.02) | 0.76 | 0.01 (-0.02 to 0.06) | 0.48 | -0.12 (-0.46 to 0.21) | 0.47 | ||
| SBP | -0.02 (-0.08 to 0.04) | 0.51 | ||||||
| DBP | -0.08 (-0.18 to 0.02) | 0.13 | ||||||
| LVEDD | 0.3 (0.13 to 0.47) |
| ||||||
| LV mass | 0.01 (-0.05 to 0.08) | 0.57 | -0.03 (-0.22 to 0.15) | 0.71 | ||||
| LV model | 0.99 (-0.18 to 2.17) | 0.1 | 0.32 (-0.1 to 0.75) | 0.14 | ||||
| Tissue tracking | -0.68 (-1.79 to 0.42) | 0.22 | ||||||
| Vendor | 0.92 (-0.07 to 1.92) | 0.08 | 0.15 (-0.1 to 0.41) | 0.25 | 0.59 (-0.36 to 1.56) | 0.22 | -6.59 (-11.3 to -1.91) |
|
| Probe | -0.70 (-1.29 to -0.1) |
| 1.36 (-0.08 to 2.81) | 0.07 | ||||
| FR | 0.007 (-0.01 to 0.03) | 0.51 | -0.001 (-0.006 to 0.002) | 0.40 | 0.07 (-0.09 to 0.23) | 0.38 | 0.55 (-0.71 to 1.82) | 0.39 |
Fig. 3Funnel plot for studies of LS
Fig. 4Normal value of LSRs. The forest plot lists the names of the studies in subgroups. The means and CIs including the results for variance, used in the inverse variance correction are shown
Fig. 5Normal value of CS. The forest plot lists the names of the studies in subgroups. The means and CIs including the results for variance, used in the inverse variance correction are shown
Fig. 6Normal value of CSRs. The forest plot lists the names of the studies in subgroups. The means and CIs including the results for variance, used in the inverse variance correction are shown
Fig. 7Normal value of RS. The forest plot lists the names of the studies in subgroups. The means and CIs including the results for variance, used in the inverse variance correction are shown
Qualitative assessment of study reporting
| Description of criteria | Possible answers |
|---|---|
| Is the hypothesis/aim/objective of the study clearly described? | Yes/No |
| Are the main outcomes to be measured clearly described in the | Yes/No |
| Are the characteristics of the patients included in the study clearly described? | Yes/No |
| Are the distributions of principal confounders clearly described? | Yes/No |
| Are the main findings of the study clearly described? | Yes/No |
| Does the study provide estimates of the random variability in the data for the main outcomes? | Yes/No |
| Were the subjects asked to participate in the study representative of the entire population from which they were recruited? | Yes/No/UTD |
| Was an attempt made to blind those measuring the main outcomes of the intervention? | Yes/No/UTD |
| Was reproducibility analysis performed? | Yes/No |
Qualitative data for eligible studies
| Study | Year | Objective defined? | Outcomes described? | Characteristics described? | Confounders described? | Main findings described? | Estimates of variability? | Heterogeneous population? | Sonographer(s) blinded? | Reproducibility performed? |
|---|---|---|---|---|---|---|---|---|---|---|
| Bussadori [ | 2009 | Yes | Yes | Yes | Yes | Yes | Yes | UTD | Yes | Yes |
| Pettersen [ | 2009 | Yes | Yes | Yes | Yes | Yes | Yes | UTD | UTD | Yes |
| Jin Yu [ | 2010 | Yes | Yes | Yes | Yes | Yes | Yes | UTD | Yes | Yes |
| Singh [ | 2010 | Yes | Yes | Yes | Yes | Yes | Yes | UTD | UTD | Yes |
| Van der Hulst [ | 2010 | Yes | Yes | Yes | Yes | Yes | Yes | UTD | UTD | No |
| Koh [ | 2010 | Yes | Yes | Yes | Yes | Yes | Yes | UTD | UTD | No |
| Cheung [ | 2010 | Yes | Yes | Yes | Yes | Yes | Yes | UTD | UTD | No |
| Marcus [ | 2011 | Yes | Yes | Yes | Yes | Yes | Yes | UTD | Yes | Yes |
| Takayasu [ | 2011 | Yes | Yes | Yes | Yes | Yes | Yes | UTD | UTD | Yes |
| Di salvo [ | 2012 | Yes | Yes | Yes | Yes | Yes | Yes | UTD | UTD | Yes |
| Fernandes [ | 2012 | Yes | Yes | Yes | Yes | Yes | Yes | UTD | Yes | No |
| Poterucha [ | 2012 | Yes | Yes | Yes | Yes | Yes | Yes | UTD | Yes | Yes |
| Hirth [ | 2012 | Yes | Yes | Yes | Yes | Yes | Yes | UTD | Yes | Yes |
| Schubert [ | 2013 | Yes | Yes | Yes | Yes | Yes | Yes | UTD | UTD | Yes |
| Sehgal [ | 2013 | Yes | Yes | Yes | Yes | Yes | Yes | UTD | Yes | Yes |
| Klitsie [ | 2013 | Yes | Yes | Yes | Yes | Yes | Yes | UTD | UTD | No |
| Klitsie [ | 2013 | Yes | Yes | Yes | Yes | Yes | Yes | UTD | Yes | Yes |
| Singh [ | 2013 | Yes | Yes | Yes | Yes | Yes | Yes | UTD | UTD | No |
| Van der Ende [ | 2013 | Yes | Yes | Yes | Yes | Yes | Yes | UTD | UTD | Yes |
| Dogan [ | 2013 | Yes | Yes | Yes | Yes | Yes | Yes | UTD | UTD | No |
| Barbosa [ | 2013 | Yes | Yes | Yes | Yes | Yes | Yes | UTD | UTD | Yes |
| Ryan [ | 2013 | Yes | Yes | Yes | Yes | Yes | Yes | UTD | Yes | Yes |
| McCandless [ | 2013 | Yes | Yes | Yes | Yes | Yes | Yes | UTD | UTD | No |
| Simsek [ | 2013 | Yes | Yes | Yes | Yes | Yes | Yes | UTD | Yes | Yes |
| Vitarelli [ | 2014 | Yes | Yes | Yes | Yes | Yes | Yes | UTD | UTD | No |
| Forsey [ | 2014 | Yes | Yes | Yes | Yes | Yes | Yes | UTD | Yes | Yes |
| Labombarda [ | 2014 | Yes | Yes | Yes | Yes | Yes | Yes | UTD | UTD | Yes |
| Binnetoglu [ | 2015 | Yes | Yes | Yes | Yes | Yes | Yes | UTD | UTD | No |
UTD unable to determine
Normal range of values for GE vendor
| LS (95 % CI) | LSRs (95 % CI) | CS (95 % CI) | CSRs (95 % CI) | RS (95 % CI) | |
|---|---|---|---|---|---|
| Neonates | -21.0 (-17.3 to -24.7) | -2.1 (-1.5 to -2.6) | -19.7 (-18.1 to -21.3) | 29.4 (24.9 to 33.9) | |
| 0-1 y | -19.3 (-17.3 to -21.2) | -20.1 (-17.1 to -23.1) | 46.3 (35.0 to 57.5) | ||
| 1-4 y | -21.7 (-19.7 to -23.8) | -19.8 (-16.2 to -23.3) | -1.73 (-1.62 to -1.83) | 53.3 (50.0 to 56.7) | |
| 5-9 y | -22.7 (-21.5 to -23.9) | -1.6 (-1.5 to -1.8) | -22.9 (-22.5 to -23.4) | -1.66 (-1.55 to -1.77) | 48.6 (39.4 to 57.8) |
| 10-14 y | -20.0 (-19.2 to -20.9) | -1.2 (-1.0 to -1.4) | -21.3 (-19.6 to -23.1) | -1.51 (-1.39 to -1.62) | 52.4 (47.4 to 57.3) |
| 15-19 y | -19.8 (-18.5 to -21.0) | -1.2 (-1.0 to -1.4) | -19.9 (-16.8 to -23.0) | -1.06 (-0.97 to -1.14) | 47.6 (37.0 to 58.1) |
| Overall | -20.6 (-20.1 to -21.2) | -1.4 (-1.3 to -1.5) | -22.5 (-22.0 to -22.9) | -1.42 (-1.37 to -1.47) | 46.8 (44.6 to 48.9) |